The latest myeloma news
The Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
RCSI research has found that venetoclax, a medication currently approved for leukaemia, has benefits for…
Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring…
Multiple myeloma remains challenging to treat. New therapeutic advances have improved outcomes, but selecting the right…
A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical…
A multicenter collaboration led by researchers at Sylvester Comprehensive Cancer Centre at the University of…
In the first clinical trial of an immunotherapy agent for people with high-risk smouldering myeloma…
A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe…
A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National…
A new agent that subverts myeloma cells from within while also subjecting them to an…